Format

Send to

Choose Destination
J Neuroimmunol. 2016 Oct 15;299:45-52. doi: 10.1016/j.jneuroim.2016.08.014. Epub 2016 Aug 16.

Methylene blue alleviates experimental autoimmune encephalomyelitis by modulating AMPK/SIRT1 signaling pathway and Th17/Treg immune response.

Author information

1
Department of Neurology, The Second Hospital of Hebei Medical University, Key Laboratory of Hebei Neurology, Shijiazhuang 050000, Hebei, China.
2
Department of Neurology, The Second Hospital of Hebei Medical University, Key Laboratory of Hebei Neurology, Shijiazhuang 050000, Hebei, China. Electronic address: guoli6@163.com.
3
Department of Neurology, The Second Hospital of Hebei Medical University, Key Laboratory of Hebei Neurology, Shijiazhuang 050000, Hebei, China. Electronic address: jack511@163.com.

Abstract

Methylene blue (MB) is an effective neuroprotectant in many neurological disorders. AMP-activated protein kinase (AMPK)/silent mating-type information regulation 2 homolog 1 (SIRT1) plays a crucial role in maintaining inflammatory responses and shows a synergistic effect on cell homeostasis. We investigated the effect of MB on experimental autoimmune encephalomyelitis (EAE), a classical animal model of multiple sclerosis (MS). MB treatment reduced the clinical scores of EAE significantly and attenuated pathological injuries in spinal cords. Furthermore, the protective effects of MB were related to the activation of AMPK/SIRT1 signaling pathway. In addition, MB treatment alleviated T helper type17 (Th17) responses and increased regulatory T cell (Treg) responses. Our findings suggest that MB could be a promising reagent to treat autoimmune diseases and MS.

KEYWORDS:

AMPK/SIRT1; Experimental autoimmune encephalomyelitis; Methylene blue; Multiple sclerosis; Th17; Treg

PMID:
27725120
DOI:
10.1016/j.jneuroim.2016.08.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center